278 related articles for article (PubMed ID: 12430923)
21. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
[TBL] [Abstract][Full Text] [Related]
22. [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Lu Y; Li F; Mu Q; Meng H; Qian W; Tong H; Mai W; Pei R; Yu M; Zhao X; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):372-7. PubMed ID: 26031521
[TBL] [Abstract][Full Text] [Related]
23. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
25. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
26. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
[TBL] [Abstract][Full Text] [Related]
27. Curative strategies in acute promyelocytic leukemia.
Tallman MS; Altman JK
Hematology Am Soc Hematol Educ Program; 2008; ():391-9. PubMed ID: 19074116
[TBL] [Abstract][Full Text] [Related]
28. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
29. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
31. Treatment of relapsed acute promyelocytic leukemia.
Lengfelder E; Gnad U; Büchner T; Hehlmann R
Onkologie; 2003 Aug; 26(4):373-9. PubMed ID: 12972706
[TBL] [Abstract][Full Text] [Related]
32. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
33. Treatment of acute promyelocytic leukemia by retinoids.
Fenaux P; Wang ZZ; Degos L
Curr Top Microbiol Immunol; 2007; 313():101-28. PubMed ID: 17217041
[TBL] [Abstract][Full Text] [Related]
34. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
35. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
36. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
37. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
Fenaux P; Chomienne C; Degos L
Semin Hematol; 2001 Jan; 38(1):13-25. PubMed ID: 11172536
[TBL] [Abstract][Full Text] [Related]
38. Treatment of acute promyelocytic leukaemia.
Fenaux P; Chomienne C; Degos L
Best Pract Res Clin Haematol; 2001 Mar; 14(1):153-74. PubMed ID: 11355929
[TBL] [Abstract][Full Text] [Related]
39. Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia.
Lo-Coco F; Ammatuna E
Curr Top Microbiol Immunol; 2007; 313():145-56. PubMed ID: 17217043
[TBL] [Abstract][Full Text] [Related]
40. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
